IRLAB Appoints Janne Backman as New Chairman of the Board

Gothenburg, September 24, 2026 – IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments for Parkinson’s disease, announces that Jan-Fredrik (“Janne”) Backman today assumes the role of Chairman of the Board. He was elected Vice Chairman at the 2026 Annual General Meeting and now succeeds Carola Lemne, who announced back in the spring that she intended to step down from the position in September.

IRLAB’s CEO intends to step down during the first quarter of 2027

New number of shares and votes in IRLAB Therapeutics AB